The Role of EGFR Tyrosine Kinase Inhibitors in the First-Line Treatment of Advanced Non Small Cell Lung Cancer Patients Harboring EGFR Mutation

By  

Current Medicinal Chemistry, Vol. 19, Iss. 20, 2012-07 ,pp. : 3337-3352

Bentham Science Publishers

Access to resources Recommend Favorite

First-line bevacizumab, cisplatin and vinorelbine plus maintenance bevacizumab in advanced non-squamous non-small cell lung cancer chemo-naïve patients

By Leon Luis   Vázquez Sergio   Gracia José Manuel   Casal Joaquín   Lazaro Martín   Firvida José Luis   Amenedo Margarita   Santome Lucia   Macia Sonia  

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 10, 2012-07 ,pp. : 1389-1396

Informa Healthcare

Access to resources Recommend Favorite

Bevacizumab as First-Line Therapy in Advanced Non-Small-Cell Lung Cancer: A Brazilian Center Experience

By >   >   >   >   Katz Artur  

Drugs in R&D, Vol. 12, Iss. 4, 2012-12 ,pp. : 207-216

Adis International

Access to resources Recommend Favorite

The Role of Pemetrexed in Second-Line Chemotherapy for Advanced Non-Small Cell Lung Cancer

By  

Current Drug Targets, Vol. 11, Iss. 1, 2010-01 ,pp. : 58-60

Bentham Science Publishers

Access to resources Recommend Favorite

Gemcitabine and vinorelbine (GV) versus cisplatin, gemcitabine and vinorelbine (CGV) as first-line treatment in advanced non small cell lung cancer: Results of a prospective randomized phase II study

By Esteban Emilio   Fra Joaquin   Fernández Yolanda   Corral Norberto   Vieitez José   Palacio Isabel   Sande José   Fernández José   Muñiz Isabel   Villanueva Noemi   Estrada Enrique   Mareque Beatriz   Uña Esther   Buesa José   Lacave Angel  

Investigational New Drugs, Vol. 24, Iss. 3, 2006-05 ,pp. : 241-248

Springer Publishing Company

Access to resources Recommend Favorite